Search
ado-trastuzumab emtansine (Kadcyla, T-DM1)
Indications:
- HER2-positive metastatic breast cancer unresponsive to trastuzumab plus chemotherapy
Contraindications:
- pregnancy
Adverse effects:
- liver toxicity, heart toxicity & death (boxed warning)
- severe life-threatening birth defects
Notes:
- distinguish from trastuzumab (Herceptin) with different dosage & treatment schedules [3]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
trastuzumab (Herceptin, Herzuma, CT-P6)
References
- FDA News Release: Feb. 22, 2013
FDA approves new treatment for late-stage breast cancer
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm
- Verma S et al.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med 2012
PMID: 23020162
- FDA MedWarch. May 6, 2013
Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication
- Potential Medication Errors Resulting from Name Confusion.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm